Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 148

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 148
---
 merger could cause DiamiR not to realize some or all of the benefits that
it expects to achieve if the merger is successfully completed within the expected timeframe. There is no guarantee that DiamiR will find
an alternative entity with which to merge.

If researchers, clinicians and healthcare administrators do not adopt DiamiR’s screening and diagnostic products, DiamiR will not achieve future sales growth.

DiamiR’s business model is heavily reliant on the adoption of
its products by researchers, clinicians, and healthcare administrators (“Industry Advocates”). These professionals play a
critical role in the healthcare ecosystem, influencing both the acceptance and the utilization of new medical technologies. A failure
to secure and maintain adoption among these groups poses a significant risk to DiamiR’s operations. New products frequently are
subject of slow adoption by healthcare specialists partly due to perceived liability risks and the uncertainty of third-party reimbursement.
It is critical to the success of DiamiR’s future sales growth that it continues to work with key opinions leaders in the field,
educate healthcare specialists about CogniMIR and other assays in development, and demonstrate the clinical utility of
its technology. If Industry Advocates do not believe in DiamiR’s products, market acceptance of its products could fail to increase
or could decrease, and its business could be harmed. Additionally, a lack of support from Industry Advocates could reduce the rate of
coverage and reimbursement by both public and private third-party payors for DiamiR’s products and services, which may further slow
the market adoption of its product by physicians, significantly reduce its ability to achieve expected revenues and prevent DiamiR from
becoming profitable. Slow adoption of DiamiR’s product by Industry Advocates would significantly reduce its ability to achieve expected
sales and could prevent DiamiR from achieving and maintaining profitability.

New product development and clinical validation involves a lengthy and complex process, and DiamiR may be unable to commercialize CogniMIR ® or any other products it may develop on a timely basis, or at all.

It takes significant time to fully develop and commercialize CogniMIR
for risk of early neurodegeneration, and therefore its launch may be delayed or may not be successful. There can be no assurance that
CogniMIR will be successful in the risk assessment of Mild Cognitive Impairment and early Alzheimer’s disease for
a variety of technical and market reasons. DiamiR’s other molecular diagnostic products, which are currently in various stages of